Anoro Ellipta Briefing Docs Promising Ahead of PADAC Meeting
The FDA released briefing documents for Glaxosmithkline plc’s Anoro Ellipta (umeclidinium/vilanterol) inhaler product for chronic obstructive pulmonary disease (COPD) ahead of a scheduled advisory committee meeting on Sept. 10. The outlook for Anoro Ellipta appears to be smooth sailing, as the FDA’s clinical review found little to criticize in GSK’s submission.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST